Not yet recruiting NCT07169149

Study About Drug Resistance of Mycobacterium Tuberculosis

— Observational Pulmonary and Extra- Pulmonary Tuberculosis (TB)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to: Registry conditions: Pulmonary and Extra- Pulmonary Tuberculosis (TB). Basic parameters: from 12 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Egypt
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Study of the Prevalence and Patterns of Drug Resistance of Mycobacterium Tuberculosis Using GeneXpert (MTB/RIF) and Xpert (MTB/XDR) Assays

Overview

Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases.

Primary outcome measures

Detection of number of cases resistant to Rifampicin and other anti- TB drugs [Time frame: within 6 months of starting treatment]

Secondary outcome measures (1)

Detection of common Risk factors associated with resistant cases [Time frame: within 6 months of starting treatment coarse]

Eligibility criteria

Inclusion criteria

geneXpert positive patients in pulmonary and extrapulmonary cases

Exclusion criteria

age below 12 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model: Case-only

Study locations

Egypt · 1 center

Sohag University — Sohag

Identifiers

NCT: NCT07169149 · Soh-Med-25-8---3MD

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗